RAJAF — Cordyceps Sunshine Biotech Holdings Co Income Statement

0.000.00%

Last trade - 00:00

HealthcareHighly SpeculativeMid Cap

Market Cap
$1.02bn
Enterprise Value
$1.02bn
Revenue
$1.25m

Annual income statement for Cordyceps Sunshine Biotech Holdings Co, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

	2020 December 31st	R2021 December 31st	R2022 December 31st	R2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	PROSPECTUS/A	20-F	20-F	20-F	20-F
Standards:	USG	USG	USG	USG	USG
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	0.135	0	0.053	0.883	1.25
Cost of Revenue
Gross Profit	0.094	0	0.04	0.766	0.534
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Total Operating Expenses	0.126	0.119	0.468	0.655	1.44
Operating Profit	0.009	-0.119	-0.415	0.228	-0.184
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	-0.012	-0.119	-0.415	0.191	-0.191
Provision for Income Taxes
Net Income After Taxes	-0.013	-0.119	-0.415	0.169	-0.226
Net Income Before Extraordinary Items
Extraordinary Items
Net Income	-0.013	-0.491	-0.72	0.752	-0.226
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	-0.013	-0.491	-0.72	0.752	-0.226
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	-0	-0.001	-0.004	0.002	-0.002